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Performance in mammography Screening
(CO-OPS): study protocol for a randomized
controlled trial
Sian Taylor-Phillips1*, Matthew G Wallis2, Helen Parsons1, Janet Dunn1, Nigel Stallard1, Helen Campbell3,
Sarah Sellars4, Ala Szczepura1, Simon Gates1 and Aileen Clarke1Abstract
Background: X-ray mammography remains the predominant test for screening for breast cancer, with the aim of
reducing breast cancer mortality. In the English NHS Breast Screening Programme each woman’s mammograms are
examined separately by two expert readers. The two readers read each batch in the same order and each indicates
if there should be recall for further tests. This is a highly skilled, pressurised, repetitive and frequently intellectually
unchallenging activity where readers examine one or more batches of 30–50 women’s mammograms in each
session. A vigilance decrement or performance decrease over time has been observed in similar repetitive visual
tasks such as radar operation.
Methods/Design: The CO-OPS study is a pragmatic, multi-centre, two-arm, double blind cluster randomised controlled
trial of a computer software intervention designed to reduce the effects of a vigilance decrement in breast cancer
screening. The unit of randomisation is the batch. Intervention batches will be examined in the opposite order by the
two readers (one forwards, one backwards). Control batches will be read in the same order as one another, as is current
standard practice. The hypothesis is that cancer detection rates will be higher in the intervention group because each
readers’ peak performance will occur when examining different women’s mammograms. The trial will take place in
44 English breast screening centres for 1 year and 4 months. The primary outcome is cancer detection rate, which will
be extracted from computer records after 1 year of the trial. The secondary outcomes include rate of disagreement
between readers (a more statistically powerful surrogate for cancer detection rate), recall rate, positive predictive value,
and interval cancer rate (cancers found between screening rounds which will be measured three years after the end of
the trial).
Discussion: This is the first trial of an intervention to ameliorate a vigilance decrement in breast cancer screening.
Trial registration: ISRCTN46603370 (submitted: 24 October 2012, date of registration: 26 March 2013).
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Epidemiology and burden of breast cancer
Breast cancer is a leading cause of mortality in women
and was the cause of death for 10,280 women in England
and Wales in 2010. It was responsible for 12% of all deaths
of women in their 50s and 8% of deaths of women in their
60s [1].
In England, up to 2.3 million women aged 47 to 73 years
are projected to have breast cancer screening each year
[2,3]. The recall rate is 40 per 1,000 women screened, and
the cancer detection rate is 7.8 per 1,000 women screened;
therefore, 32 healthy women per 1,000 screened are
recalled for further tests (false-positive recalls) [3].
Currently, 66% of all breast cancers in women 50 to
64 years of age in England are detected by screening [3].
This occurs because some women choose not to be
screened and the screening test is not perfect. Cancers
diagnosed between screens (interval cancers) either grow
de novo between screening rounds or are not seen or
picked up by the programme. As with all screening pro-
grammes, the National Health Service Breast Screening
Programme (NHSBSP) aims to keep interval cancers to a
minimum, with a target rate of 2.3 per 1,000 women [4,5].
However, these are difficult targets; the rates achieved are
closer to 3 per 1,000 women [6].
When investigating methods of improving cancer detec-
tion, one has to be mindful of the potential for increasing
overdiagnosis and overtreatment (that is, cancers detected
at screening and treated which never would have pre-
sented or caused problems within the patient’s life). It is
important to ensure that any additional test or new meth-
odology that increases cancer detection has a matched fall
in interval cancer rates.
Existing knowledge
In the NHSBSP, each woman’s mammograms are exam-
ined separately by two specialists, each of whom indicates
whether there should be a recall for further tests. These ex-
perts are radiologists, advanced radiography practitioners
or breast clinicians, (henceforth referred to for simplicity
as readers). If the two readers disagree, the case is re-
ferred for arbitration, usually by a third reader or a
group of readers. For workflow reasons, 30 to 50 women’s
mammograms are grouped together into a batch and are
typically read without a break. In a mammography reading
session, a reader may examine one, two or more batches.
On average, readers assess two women’s mammograms
per minute [7]. This is a highly skilled, pressurised and re-
petitive, but frequently intellectually nonchallenging, ac-
tivity. A vigilance decrement manifesting as a performance
decrease over time has been observed in a wide range of
similar repetitive visual tasks such as radar operation [8].
Current practice is for both readers to examine each
batch of mammograms in the same order as one another;thus any vigilance decrement will occur when reading the
same woman’s mammograms. We hypothesise that pre-
senting batches to the first and second readers in a diffe-
rent order from one another may increase the sensitivity
of screening. A trial is required to determine whether such
improvements would be realised in practice.
Methods/Design
Our hypothesis is that if the second reader examines the
batch of mammograms in the order opposite that of the
first reader, the overall cancer detection rates will in-
crease. This will happen through increasing rates of dis-
agreement between readers because each reader’s peak
performance will occur when examining different cases.
The trial will be carried out in accordance with Good
Clinical Practice (GCP) as detailed in the Medical Re-
search Council GCP guidelines [9] and the following
protocol. The trial will be reported in line with the
CONSORT (Consolidated Standards of Reporting Trials)
statement [10] and the further guidance available for
cluster randomised controlled trials [11]. Ethical ap-
proval was granted by the Coventry and Warwickshire
National Health Service (NHS) Research Ethics Commit-
tee on 27 June 2012 (Reference 12/WM/0182). Formal
approval was also granted by the Research and Develop-
ment office of each NHS Trust involved in the study.
Trial summary
The trial is a pragmatic, multicentre, two-arm, double-
blind, cluster randomised controlled trial of a computer
software intervention designed to reduce the effects of a
vigilance decrement in breast cancer screening. The inter-
vention changes the order in which the readers examine
the batches of mammograms. The centres will be NHSBSP
centres with digital mammography equipment. A cluster
for randomisation comprises a batch of mammograms (ap-
proximately 30 to 50 women’s mammograms). Intervention
batches will be examined in the opposite order by the two
readers (one in appointment order and one in reverse ap-
pointment order). Control batches will be read in the same
order as one another as is current standard practice. The
unit for analysis is the individual woman’s outcome.
Standard practice is for both readers to read the batch
of mammograms in the order in which the women were
booked in for their appointments. In the control group,
both readers will read each batch in the same order as
one another, but this may be in appointment order or in
reverse appointment order (↓↓ or ↑↑). In the interven-
tion group, both readers will read the mammograms in
the order opposite one another (↓↑ or ↑↓). This design
blinds the readers because if they read in the reverse
order, they will not know if they are reading the inter-
vention or control group. The study software which will
be used to run the trial will be embedded in the National
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every English breast screening centre as part of routine
updating of the NBSS system.
The pilot study will be conducted in three screening
centres for 2 weeks to ascertain practical issues with im-
plementation and to test the data collection tool, which
will extract the results from the screening centres’ elec-
tronic database (NBSS). Concurrently, a survey of all
English breast screening centres will be conducted to
ascertain key characteristics relevant to the trial which
may differ between centres, such as the method of arbi-
tration used. These details will be described in the re-
port and considered in the statistical analysis of the trial
to ascertain whether the effectiveness of the interven-
tion is affected by these characteristics.
The trial will last 16 months in 44 centres and will in-
clude all women attending routine digital mammography
screening during the study period. The data gathered
during the first 12 months (1.1 million women) will be
derived from the NBSS database to determine whether
the intervention has increased the cancer detection rate.
These data will include all items for the primary and sec-
ondary analyses, with the exception of interval cancer
rate. The interval cancer data will be collected 3 years
after the end of the study period to ascertain whether
there has a been a decrease in the rate of interval can-
cers and therefore whether the intervention reduced the
number of cancers missed at screening.
Trial aims and outcomes
The primary aim of the trial is to determine whether
presenting the cases to the first and second readers in
the order opposite one another increases the cancer de-
tection rate (true-positive rate). The secondary aims and
outcome measures of the trial are as follows:
1. Is there a difference in the number of disagreements
between readers in each study arm? This is the
proposed mechanism by which an increase in cancer
detection rate occurs and therefore acts as a
surrogate outcome, particularly if the effect size is
smaller than anticipated or recruitment targets are
not met. The rate of disagreement refers to the
proportion of cases for which one reader thought
the case should be recalled and the other reader
thought the case should not be recalled.
2. Is there a difference in 3-year interval cancer rate in
each study arm? Furthermore, as the interval cancer
rate can be considered an approximation of the
false-negative rate, is this change (if any) concurrent
with changes in the cancer detection rate between
study arms (primary outcome)? The interval cancer
rate is measured as the rate of cancers detected
symptomatically in the 3 years subsequent toscreening and therefore will be collected 3 years
after the trial implementation is complete.
3. Do the recall rate and positive predictive value
(PPV) differ between the study arms?
4. With regard to NHS considerations, is the
intervention cost-effective when compared with the
control arm? The lifetime cost-effectiveness of the
intervention will be modelled using the primary out-
come from the trial. Are there any effects introduced
by the trial methodology? Specifically, are the cancer
detection and recall rates affected by introducing re-
verse reading order? The cancer detection rate and
the recall rate for both versions of the control arm
(↓↓ and ↑↑) will be compared to measure any ad-
verse effects of reading in reverse order.
Statistical considerations
Primary analysis
To determine whether the cancer detection rate is higher
in the intervention group than in the control group, a
two-tailed analysis will be conducted using a multilevel lo-
gistic regression model. Levels in the model will be case,
batch and centre. To prevent overfitting, each level will be
included in the final model only if it explains a sufficient
portion of the variability and improves model fit. The
intervention may be more effective in certain subgroups,
particularly younger women, women whose cases are read
at the very beginning or end of the batch and the first
batches to be examined in a workday. These subgroups
will be analysed separately as specified in the statistical
analysis plan and agreed by the Trial Steering Committee.
Analysis will be conducted as intention to treat, with
all cases randomised included in the analysis. Missing
data through loss to follow-up will occur in both groups
for women who are recalled from screening but either
did not attend the follow-up appointment or for whom
no records exist in the database concerning the results
of that appointment. Multiple imputation and sensitivity
analyses to examine the effects of any missing data on
the model will be considered if appropriate.
Secondary analyses
To determine whether the disagreement rate between
readers, interval cancer rate and recall rate are different
between the intervention and control groups (secondary
aims 1, 2 and 3), the same methods as described for the
primary analysis above will be used. The PPV of cancer
detection in each study arm will be calculated as the
proportion of women recalled who are found to have
cancer (secondary aim 3).
The effects of the trial introducing the reverse read-
ing order (secondary aim 5) will also be analysed. The
recall and cancer detection rates for the two reading
groups which make up the control arm will be compared
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same way as the primary analysis, but using reading order,
not trial group membership, as the predictor of cancer de-
tection rate and recall rate.
To generate secondary outcome 4 (estimates of cost-
effectiveness), the primary outcome from the trial will be
used as an input into a health economic model of breast
cancer screening. This model will be developed by expan-
ding an earlier breast cancer model described by Campbell
et al. [12] and will predict lifetime costs and effects for both
the intervention and control arms. The model simulates
the underlying breast cancer disease process according to
prognosis upon presentation and includes adjuvant therap-
ies, the long-term risk of recurrence (both local and meta-
static) and treatment and long-term survival following
recurrence. It will be used to model the changes in costs,
life-years and quality-adjusted life years brought about by a
potential change in the cancer detection rate.
Power and sample size
Currently, 14,700 cancers are detected by screening
each year, and the cancer detection rate is 7.8 per
1,000 women screened [3]. Detection of one extra can-
cer case per 2,000 women screened would increase the
cancer detection rate to around 8.3 cancers per 1,000
women screened. To detect this change of 0.5 cancers
per 1,000 women using a two-tailed test at 80% power
and 5% significance, 501,361 women are required in
each arm.
As randomisation occurs at the batch level, however,
collected data are clustered and this must also be taken
into consideration. The sample size of a clustered study
must be increased by the design effect (DE), which is
calculated as DE = 1 + (m − 1)ρ for a given intraclass
correlation coefficient (ICC; ρ) and cluster size (m). The
ICC was calculated using previous data in a logistic bino-
mial Gaussian model (method B) with 1,000 Monte Carlo
simulations [13]. Hence, using the ICC of 0.002 and a clus-
ter (batch) size of 40 women produces a DE of 1.09, in-
creasing the sample size required to 546,890 in each arm.
There is no adjustment for crossover, because once the
intervention is applied to a screening centre, each batch
will automatically be randomly assigned to the interven-
tion or control group by the NBSS computer system and
the intervention will be applied automatically by the same
system. A woman could be lost to follow-up if her NBSS
records have not been updated or if she is recalled from
screening for further tests and does not attend her
follow-up appointment. This is uncommon, however, so
we have assumed low dropout rates of 3,500 women in
each arm, inflating the sample required to 550,390 in
each arm. Therefore, as detailed in Figure 1, the overall
sample size required is for 1,100,780 women, or 44 breast
screening centres for 1 year (On the basis that in Englandthere are 82 centres each screening around 25,000 women
per year).
Recruitment
There are 80 breast screening centres in England. About
44 breast screening centres will be recruited into the
trial (depending on centre size), which will last for 1
year, 4 months. After the first year of the trial (allowing 2
months for follow-up appointments to determine which
women have cancer), the data for 1 year of screening at 44
centres will be downloaded and analysis of the primary
outcome of cancer detection rate and the secondary out-
comes will be completed. Analysis of missed cancer rates
will be undertaken at 3 years after completion of the ad-
ministration of the intervention.
There will be no extra time commitment for NHS staff
in administering the trial at each centre, as the design is
fully computerised and changes to batch reading orders
will be automatically downloaded using each centre’s lat-
est software update. Importantly, this scheme is antici-
pated to help with reaching recruitment targets.
Eligibility
To be included, screening centres must use double-reading
of screening mammograms and must have at least one
piece of digital mammography equipment used for scree-
ning. All women who undergo mammography screening
using digital equipment during the study period at the
study centres will be included.
Centres which use single reading of mammograms,
centres that have no digital mammography equipment
used for screening (for example, the software interven-
tion does not work in the old equipment) and women
who attend symptomatic breast clinics will be excluded.
Postrandomisation withdrawals and exclusions
Centres participating may withdraw from the trial at any
time without prejudice. Upon withdrawal, or at any time
before the data is analysed, centres can choose whether
their data is collected and used in the analysis. Initial sur-
vey results describing centre characteristics will be used to
analyse patterns of withdrawals from the trial, unless the
centre requests that their data not be used in this way.
Compliance and contamination
Compliance is expected to be very high because, after
centre-level consent is given, all implementation is auto-
mated. In addition, deviation from the protocol would be
very difficult. There is no method available to move cases
between intervention and control groups. Case order can
be changed manually by selecting the ‘ignore’ option ra-
ther than inputting a screening result, so that either the
mammogram can be reviewed at a later stage or a result
can be input and revised later. These events will change
Figure 1 Planned baseline CONSORT 2010 flow diagram for cancer detection analysis. All batches of women attending routine digital
mammography screening at participating centres during the trial will be randomised to either the intervention or control group. Follow-up data
may not be available for a small proportion of women who either do not attend a recall for assessment or for whom records are not updated at
the point of data collection. NBSS, National Breast Screening Service.
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ation. However, analysis will be based on intended order
of reading. Data will also be collected on actual reading
order to measure levels of contamination and their effects
on outcomes. These effects are expected to be extremely
small (on the order of 1 per 500 cases) because screening
is a fast-moving, high-volume activity, and there is little
time in practice to change reading order or to come back
to cases at a later stage. Full data management procedures
can be found in the statistical analysis plan.Consent
Informed consent will be obtained at the centre level
from the director of the service, who is also usually the
lead reader. Consent will be obtained at the centre
level rather than by patient or reader because it is at
this level that the intervention is applied. In addition,
the intervention can be considered an alternative form
of standard practice because no aspect of the way in
which the mammograms are reviewed or evaluated is
altered other than the reading order.
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in the first instance by email introducing the study with
a copy of the participant information sheet and informed
consent form attached. They will then receive a follow-
up telephone call 1 week later. Each centre director will
be offered a copy of the research protocol and the Inte-
grated Research Application System ethics form and a visit
from one member of the investigation team to introduce
the study if desired. The study software embedded in the
NBSS software will remain inactive until a signed consent
form is received from the centre and local research and
development approvals are granted, at which point it can
be activated simply and quickly. The study can commence
in each centre by simply changing the software settings to
activate the intervention.
In the unlikely event that information becomes available
which may be relevant to the participant’s willingness to
continue participating in the trial (for example, findings
from other research studies), then the directors of every
participating breast screening centre will be informed im-
mediately by email and follow-up telephone call.
Recruitment and randomisation
The rate of accrual will be monitored at the centre level.
If it falls appreciably below the projected level, the rea-
sons will be identified and remedial actions will be taken
to protect the power of the trial and alleviate concerns
about selective entry and other aspects of quality. Ran-
domisation will be automatically computer-generated at
the point at which the batch is ready to be read on the
NBSS system. Only batches of cases to be read as part of
the NHS breast screening programme will be rando-
mised. Cases from symptomatic clinics will be excluded
prior to randomisation. Randomisation will be carried
out with equal probability to one of four groups: control
(both read in appointment order: ↓↓), control (both read in
reverse appointment order: ↑↑), intervention (first
reader in appointment order and second reader in re-
verse appointment order: ↓↑) and intervention (first
reader in reverse appointment order and second reader
in appointment order ↑↓).
Blinding
The women screened will not be aware of whether their
mammograms are read as part of an intervention or a
control batch. The readers will not know the arm of the
trial to which each batch has been assigned, because
batches will be read in appointment order and reverse
appointment order in both arms of the trial.
Discussion
The experimental design is between subjects, so readers
will not be burdened with reading cases twice (once in each
experimental condition). This design has lower statisticalpower than a within-participant approach, however, so re-
cruitment targets are high to achieve 80% power. Sensitivity
analysis for the estimate of effect size indicates that it is very
sensitive to small changes in effect size. If the effect size is
as low as 200 extra cancers detected per year in England, it
may still be considered clinically significant, but overall
sample size would need to be 14 million women to detect
such an effect. Achieving a sample of this size would be un-
realistic; therefore, there is a risk of the trial being under-
powered. However, an effect size of 200 extra cancers
detected in England each year would be detectable in the
form of a surrogate for cancer detection rate, which is the
rate of disagreements between readers. This parameter is
included as a secondary outcome. If recruitment targets
are not met, then the rate of disagreements, as a surrogate
for cancer detection rate, may have to be used as the pri-
mary outcome.
One possible mechanism for harm from the interven-
tion is associated with reading the cases in reverse ap-
pointment order, which is not currently standard practice.
To blind the readers to group allocation, however, reading
in reverse appointment order is present equally in the
intervention and control groups, so a two-tailed test
would not detect this harm. Therefore, a secondary ana-
lysis of recall rate and cancer detection rate of cases read
in appointment order and reverse appointment order will
be carried out to determine whether reading a batch in re-
verse appointment order affects performance.
This study is a pragmatic multicentre, two-arm, double-
blind, cluster randomised controlled trial of a computer
software intervention designed to reduce the effects of a
vigilance decrement in breast cancer screening. The inter-
vention and randomisation are applied automatically using
computer software, thus reducing the cost of running the
trial and limiting the possibility of allocation and treat-
ment bias. This study design also reduces the administra-
tive burden on participating centres, thus removing one of
the barriers to participation. The trial is double-blinded
because neither the women screened nor the readers will
be aware of whether each batch is in the intervention or
control group.Trial status
The trial has National Health Service ethical approval,
and the software has been activated in 45 centres in
the United Kingdom. Data collection is due to start in
February 2014.Trial steering committee
The fellowship advisory group also acts as the trial stee-
ring committee. There is no need for a data-monitoring
committee, as there will be no interim data available to
monitor.
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